Prague.bio’s Post

Hello everyone, As my network has increased substantially during the recent months, I am re-sharing a material that may interest many of you. It is a great book I edited a few years ago for Elsevier on #Biotechnology, #Pharmacy, and #Techtransfer. But that does not accurately describe the work put together by highly competent authors from Canada, Brazil, Germany, Italy, Denmark, Spain, UK, and more. One central aspect of this publication is the interface of #researchcenters, #privatesector, and the #publicsector, coordinating and fostering high-quality science. It includes many examples of products made available to the public and patients, highlighting the crucial aspect of having research with #purpose (nothing against "pure science"). The aspects covered go from #biopharmaceuticals over #diagnostics, bio-based #food, to #startups, #globalenterprises, and governamental initiatives, such as #horizoneurope. It also covers an ambitious curriculum, from the very early steps of #biotechnology (#Leeuwenhoek, #LouisPasteur, #RobertKoch, #MarieKrogh, etc.) to #recombinantDNAtechnology, #CRISPR, spiced with stories of personalities like #DorothyHodkin and #RosalindFranklin, the role of biotechnology in countries like #Japan, #Germany, #Switzerland, #Denmark, and #USA. Besides, you can find interesting facts about how innovative biotech companies (e.g., #Genentech, #Amgen, #Genzyme) and pharmaceutical players (e.g., #Roche, #Lonza, #NovoNordisk, #EliLilly, #Boehringer) started. In summary, the book is designed to serve as a consulting material for begginers and seasoned professionals, as a lecturing material with #applications and perhaps as strategic consultation for governmental bodies. If you have interest, here is the link: https://lnkd.in/gqYxuyuW, and you can find a flyer below 😊. Of course, I am glad that such work has equipped me to serve our customers at NNIT with great technical and domain knowledge to provide competent and well-informed services 😉. #bioeconomy #fermentation #medicine #innovation #proteins #qualitybydesign #biomanufacturing #peptides #smallmolecules

Selecting the right cells is crucial for successful drug testing. It helps is understand how the drug interacts with a living system. But with a vast array of cell types available, how do you choose the best ones for your experiment? We have covered some key considerations, but there is always more to learn! Share your experiences and factors you consider when choosing cells for drug testing in the comments below. Empower Your Research: Explore Our Cell Collection Ready to take your #drugdiscovery to the next level? Browse our extensive collection of high-quality #stemcells and #primarycells at kosheeka.com. Find the perfect cells to propel your research forward! #cellculture #biotechnology #research #kosheeka #cellbiology

📃Scientific paper: Unearthing the fungal endophyte Aspergillus terreus for chemodiversity and medicinal prospects: a comprehensive review Abstract: Aspergillus terreus microorganism represents a promising prospective source for drug discovery since it is rich in diverse kinds of bioactive secondary metabolites. It contributed to many biotechnological applications and its metabolites are used in the synthesis of certain pharmaceuticals and food products, in addition to its useful uses in fermentation processes. There are about 346 compounds identified from marine and terrestrial-derived A. terreus from 1987 until 2022, 172 compounds of them proved a vast array of bioactivity. This review aimed to create an up-to-date comprehensive literature data of A. terreus’s secondary metabolites classes supported by its different bioactivity data to be a scientific record for the next work in drug discovery. Continued on ES/IODE ➡️ https://etcse.fr/rTQE ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Unearthing the fungal endophyte Aspergillus terreus for chemodiversity and medicinal prospects: a comprehensive review Abstract: Aspergillus terreus microorganism represents a promising prospective source for drug discovery since it is rich in diverse kinds of bioactive secondary metabolites. It contributed to many biotechnological applications and its metabolites are used in the synthesis of certain pharmaceuticals and food products, in addition to its useful uses in fermentation processes. There are about 346 compounds identified from marine and terrestrial-derived A. terreus from 1987 until 2022, 172 compounds of them proved a vast array of bioactivity. This review aimed to create an up-to-date comprehensive literature data of A. terreus’s secondary metabolites classes supported by its different bioactivity data to be a scientific record for the next work in drug discovery. Continued on ES/IODE ➡️ https://etcse.fr/rTQE ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Unearthing the fungal endophyte Aspergillus terreus for chemodiversity and medicinal prospects: a comprehensive review Abstract: Aspergillus terreus microorganism represents a promising prospective source for drug discovery since it is rich in diverse kinds of bioactive secondary metabolites. It contributed to many biotechnological applications and its metabolites are used in the synthesis of certain pharmaceuticals and food products, in addition to its useful uses in fermentation processes. There are about 346 compounds identified from marine and terrestrial-derived A. terreus from 1987 until 2022, 172 compounds of them proved a vast array of bioactivity. This review aimed to create an up-to-date comprehensive literature data of A. terreus’s secondary metabolites classes supported by its different bioactivity data to be a scientific record for the next work in drug discovery. Continued on ES/IODE ➡️ https://etcse.fr/rTQE ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📖 ‘Ambition and urgency’ is the call from EuropaBio in response to the EC’s newly published 'Boosting Biotechnology and Biomanufacturing in the EU' Initiative. It’s getting the headlines right, but needs to convert policy rhetoric into action and keep the momentum going now to resolve immediate issues. ➡ Read EuropaBio’s response to the Initiative and come with us on the journey to its delivery. https://lnkd.in/eu8wYUT4

𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄 𝘁𝗵𝗮𝘁, 𝗶𝗻 𝘁𝗵𝗲 𝘀𝗲𝗮𝗿𝗰𝗵 𝗳𝗼𝗿 𝗻𝗲𝘄 𝗱𝗿𝘂𝗴𝘀, 𝘁𝗵𝗲 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝘂𝘀𝗲𝘀 𝘁𝘄𝗼 𝗺𝗮𝗶𝗻 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀? One is the 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗼𝗳 𝗲𝗻𝘁𝗶𝗿𝗲𝗹𝘆 𝗻𝗲𝘄 𝘀𝘂𝗯𝘀𝘁𝗮𝗻𝗰𝗲𝘀, often starting with the exploration of natural ecosystems and the bioprospecting of plants, fungi or bacterias. This was exactly what I did in my master’s research, where I studied actinobacteria isolated from mangroves—unique microorganisms in these rich ecosystems with great potential for producing innovative molecules with therapeutic activity. This discovery process includes several essential stages, which can take 𝟭𝟬 𝘁𝗼 𝟭𝟱 𝘆𝗲𝗮𝗿𝘀 𝗼𝗳 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵: -Collection and Isolation: Samples are collected from the environment, and the bacteria are isolated and cultivated in the lab. -Biological Activity Screening: The isolated bacteria are screened to identify compounds with promising therapeutic activity. -Extraction and Chemical Characterization: Active compounds are extracted, then chemically characterized using advanced techniques such as chromatography and mass spectrometry. -Efficacy Testing: The compounds are tested for safety and efficacy, first on cells and then on animal models, before advancing to further development. This pathway can reveal innovative compounds, like antibiotics and antivirals, though it is complex and time-intensive. For this reason, many industries choose a second approach: 𝗺𝗼𝗱𝗶𝗳𝘆𝗶𝗻𝗴 𝗸𝗻𝗼𝘄𝗻 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀. This process involves adapting familiar chemical structures to create drugs that are more effective and safer, in less time and at a lower cost. This “drug optimization” facilitates the creation of new formulations, making innovation accessible and agile. 𝗧𝗵𝗲𝘀𝗲 𝘁𝘄𝗼 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀—𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻—𝗮𝗿𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝗿𝘆 𝗮𝗻𝗱 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗳𝗼𝗿 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻. 𝗪𝗵𝗶𝗹𝗲 𝗻𝗲𝘄 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀 𝗮𝗿𝗲 𝗳𝘂𝗻𝗱𝗮𝗺𝗲𝗻𝘁𝗮𝗹 𝘁𝗼 𝘁𝗮𝗰𝗸𝗹𝗶𝗻𝗴 𝘂𝗻𝗿𝗲𝘀𝗼𝗹𝘃𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀, 𝘁𝗵𝗲 𝗮𝗱𝗮𝗽𝘁𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗲𝘅𝗶𝘀𝘁𝗶𝗻𝗴 𝘀𝘂𝗯𝘀𝘁𝗮𝗻𝗰𝗲𝘀 𝗲𝗻𝗮𝗯𝗹𝗲𝘀 𝗿𝗮𝗽𝗶𝗱 𝗮𝗻𝗱 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀. This diversity of approaches keeps the science of drug discovery vibrant and continuously promising. #Biotechnology #PharmaceuticalInnovation #DrugDiscovery #Science #Health #Bioprospecting

🌍✈️ Galicia Biotechnology will travel to the #USA to strengthen ties with leaders in the #biotech sector. This week, 8 entities from Galician bioregion (Bioga, Cluster Saúde de Galicia, CSG, Galaria EPSS, SA, Instituto de Investigación Sanitaria de Santiago de Compostela, CICA UDC Centro Interdisciplinar de Química e Bioloxía, AMSbiopharma, AFFINImeter, Keybiological) in collaboration with the Galician Innovation Agency Axencia Galega de Innovación, will take part in a strategic mission to North Carolina. During this visit, we will meet with key players in the biotechnology sector, research institutions, and innovative companies to explore opportunities for investment and collaboration. North Carolina is one of the most important biotechnology hubs in the United States, driven by the Research Triangle Park, the largest research park in the country and one of the largest in the world, located between Raleigh, Durham, and Chapel Hill. This park is home to a dense concentration of biotechnology companies, pharmaceutical research, academic institutions, and innovation centers, housing more than 600 high-tech and life science companies. With this initiative, we aim to strengthen our biotechnology ecosystem and position ourselves as a reference point in Europe. #biotech #innovation #galiciabiotech #tech #innovate #biospain

“Anything in the IRA [Inflation Reduction Act] that stops us from using drugs to their maximum potential is a mistake,” says Emil Kakkis. At the Stanford Biodesign Policy Program’s Health Technology Innovation Policy Conference 2024, Kakkis and other speakers on the biotechnology panel — Jeff Allen, Ken Drazan, Peter Kolchinsky, and Peter Marks — discussed the implications of the IRA on orphan drugs, and the unintended negative consequences on patients and drug manufacturers. Acknowledging that the IRA has accomplished some important things that will make a real difference in affordability and access to healthcare, the panelists highlighted, however, that the impact for orphan drug development may be felt in the next few decades as companies limit investment/research into additional indications for orphan drugs. The panelists also discussed the potentially transformative impact of cell and gene therapies and what can be done from a regulatory perspective to support that ecosystem. If you were unable to join us, here’s a replay of the discussion https://lnkd.in/gji8d5XE Many thanks to Stanford Biodesign’s D. Michael Ackermann, director, biotechnology, who moderated the session. #healthpolicy #biotech #healthtech #SBDHealthtechInnovationPolicy

📢 World Leaders Discuss Europe's Cluster Policy for Green Digital and Biotech Transitions 💥 More than 900 experts from clusters and the EU Commission gathered in Brussels for the European Cluster Conference. They discussed cluster policy needed for Europe to become a world leader in green and digital transitions and biotechnology. 🌍💪🏼 Compared to the US and China, EU biotech clusters lack support in funding, resources, and scaling up bioproduction. The European Federation of Pharmaceutical Industries and Associations suggested focusing resources in a few large clusters. However, some experts emphasized the importance of networking and mapping existing expertise in topic-specific metaclusters. 🌐🔬 Jan-Philippe Kramer, from the European Cluster Collaboration Platform, presented Innovation scores, showing that China has caught up with the EU in terms of innovation. Clusters play a crucial role in the innovation process, but their sector-specific needs must be better understood and heard. 👩💼💻💡 #BioprocessUpdates #EuropeanClusterConference #clusterpolicy #greentransitions #digitaltransitions #biotechnology #EUbiotechclusters #funding #resources #scalingup #bioproduction #networking #metaclusters #innovation #sectorspecific #EU ▷ Read the full article here: 📎 https://lnkd.in/d6qjD5ce